DJI
-0.32%
SPX
-0.01%
IXIC
+0.05%
FTSE
+0.22%
N225
-0.21%
AXJO
+1.37%

SLRX beat EPS expectations by 68.95%

Nov 22, 2024, 11:31 PM
7.48%
What does SLRX do
Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company based in Houston, Texas, focuses on developing innovative cancer treatments, including seclidemstat and SP-3164. The company went public on January 29, 2015.
Salarius Pharmaceuticals (SLRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Salarius Pharmaceuticals's actual EPS was -$0.76, beating the estimate of -$2.45 per share, resulting in a 68.95% surprise.
📡️ Health Care
Earnings Surprise

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

© 2024 Cashu PTY LTD.